These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38791148)
1. MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer. Iida M; Crossman BE; Kostecki KL; Glitchev CE; Kranjac CA; Crow MT; Adams JM; Liu P; Ong I; Yang DT; Kang I; Salgia R; Wheeler DL Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791148 [TBL] [Abstract][Full Text] [Related]
2. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis. Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829 [TBL] [Abstract][Full Text] [Related]
3. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568 [TBL] [Abstract][Full Text] [Related]
4. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer. Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002 [TBL] [Abstract][Full Text] [Related]
5. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway. Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829 [TBL] [Abstract][Full Text] [Related]
6. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778 [TBL] [Abstract][Full Text] [Related]
7. Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells. Wu R; Li K; Yuan M; Luo KQ Oncogene; 2021 Mar; 40(12):2165-2181. PubMed ID: 33627781 [TBL] [Abstract][Full Text] [Related]
8. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040 [TBL] [Abstract][Full Text] [Related]
9. Rhophilin-associated tail protein 1 promotes migration and metastasis in triple negative breast cancer via activation of RhoA. Liu Q; Huang X; Li Q; He L; Li S; Chen X; Ouyang Y; Wang X; Lin C FASEB J; 2020 Aug; 34(8):9959-9971. PubMed ID: 32427399 [TBL] [Abstract][Full Text] [Related]
11. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797 [TBL] [Abstract][Full Text] [Related]
12. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer. Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833 [TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition. Das K; Paul S; Singh A; Ghosh A; Roy A; Ansari SA; Prasad R; Mukherjee A; Sen P J Biol Chem; 2019 Sep; 294(37):13681-13696. PubMed ID: 31341019 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934 [TBL] [Abstract][Full Text] [Related]
15. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. Bilir B; Kucuk O; Moreno CS J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694 [TBL] [Abstract][Full Text] [Related]
16. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1. Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190 [TBL] [Abstract][Full Text] [Related]
17. Genomic regulation of invasion by STAT3 in triple negative breast cancer. McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809 [TBL] [Abstract][Full Text] [Related]
18. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795 [TBL] [Abstract][Full Text] [Related]
19. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells. Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272 [TBL] [Abstract][Full Text] [Related]
20. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity. Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]